- |||||||||| Review, Journal: Drug-Drug Interactions of FXI Inhibitors: Clinical Relevance. (Pubmed Central) - Mar 27, 2024
These characteristics may be useful to differentiate their use with the direct oral anticoagulant (DOAC) anti -FXa (rivaroxaban, apixaban, edoxaban) and thrombin (dabigatran), whose pharmacokinetics are strongly dependent from P-gp inhibitors/inducers. In the present review, we summarize the current clinical evidence on DDIs of new anti FXI with CYP450/P-gp inhibitors and inducers and indicate potential differences with DOAC anti FXa.
- |||||||||| dabigatran etexilate / Generic mfg.
Journal: Dabigatran-related serious medication errors: an analysis using data from VigiBase. (Pubmed Central) - Mar 14, 2024 Although the incidence of MEs with clinical consequences in the use of dabigatran cannot be determined, attention should be paid to selection of the appropriate dose to a right patient in the prescription, and to patient compliance and storage in drug administration. The patient harm mainly manifested itself as bleeding or ischemia including fatal outcome in rare patients.
- |||||||||| Savaysa (edoxaban) / Daiichi Sankyo
Journal: Pearls and Pitfalls in the Measurement of Direct Oral Anticoagulants. (Pubmed Central) - Mar 9, 2024 Separation methods based on liquid chromatography and mass spectrometry may be clinically questionable, since they measure the concentration rather than the actual inhibitory effect of DOACs, are relatively expensive, cumbersome and time consuming, and therefore seem unsuitable for most conditions requiring urgent clinical decision making. A proposed approach therefore involves establishing a network of routine clinical laboratories, designating a reference center where DOAC tests could be available 24/7, establishing a clear diagnostic care pathway for ordering the tests from the laboratory and standard operating procedures for performing them, the use of the diluted thrombin time for dabigatran and anti-FXa assays (drug-calibrated) for rivaroxaban, apixaban, and edoxaban, as well as providing expert advice throughout the testing process, from ordering to interpretation of results.
- |||||||||| bivalirudin / Generic mfg.
Journal, Adverse events: Bivalirudin versus Heparin on Net Adverse Clinical Events, Major Adverse Cardiac and Cerebral Events, and Bleeding in Elderly Chinese Patients Treated with Percutaneous Coronary Intervention. (Pubmed Central) - Mar 8, 2024 A proposed approach therefore involves establishing a network of routine clinical laboratories, designating a reference center where DOAC tests could be available 24/7, establishing a clear diagnostic care pathway for ordering the tests from the laboratory and standard operating procedures for performing them, the use of the diluted thrombin time for dabigatran and anti-FXa assays (drug-calibrated) for rivaroxaban, apixaban, and edoxaban, as well as providing expert advice throughout the testing process, from ordering to interpretation of results. No abstract available
- |||||||||| rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Journal, Real-world evidence, Real-world: Real-world experience of direct oral anticoagulant use in a single pediatric center. (Pubmed Central) - Mar 7, 2024 However, this observation may be attributed to patients who had ongoing risk factors, as well as a longer duration of study follow-up. Additional multicentered outcome studies evaluating DOAC use in children are needed to determine long-term recurrence and HMB risks.
- |||||||||| Praxbind (idarucizumab) / Boehringer Ingelheim, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Journal: Direct oral anticoagulants in trauma patients. (Pubmed Central) - Mar 6, 2024 Compared to VKAs, DOACs do not carry a higher bleeding risk. DOAC specific antagonists facilitate the individual bleeding management.
- |||||||||| Praxbind (idarucizumab) / Boehringer Ingelheim, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Journal: Antidote vs. unspecific hemostatic agents for the management of direct oral anticoagulant-related bleeding in trauma. (Pubmed Central) - Mar 6, 2024 Current guidelines recommend specific antidots and PCCs in DOAC-related major bleeding. Prospective randomized trials comparing specific vs. nonspecific hemostatic agents in the perioperative setting are needed to evaluate the effectiveness and safety of the hemostatic agents.
- |||||||||| bivalirudin / Generic mfg.
Journal: Bivalirudin: The misunderstood alternative to heparin. (Pubmed Central) - Mar 5, 2024 Prospective randomized trials comparing specific vs. nonspecific hemostatic agents in the perioperative setting are needed to evaluate the effectiveness and safety of the hemostatic agents. No abstract available
- |||||||||| Savaysa (edoxaban) / Daiichi Sankyo
Journal: Development of a Rapid Qualitative Screen for Anticoagulant Presence. (Pubmed Central) - Mar 4, 2024 After using Argatroban, there was no increase in the risk and mortality of intracranial hemorrhage and other bleeding sites. Our study demonstrates that commonly available heparin anti-Xa activity and TT assays can be used to qualitatively detect DOACs and fondaparinux and provides a method to establish a qualitative interpretation.
- |||||||||| warfarin / Generic mfg.
Journal: Balfaxar: Another four-factor PCC for warfarin reversal. (Pubmed Central) - Mar 2, 2024 Our study demonstrates that commonly available heparin anti-Xa activity and TT assays can be used to qualitatively detect DOACs and fondaparinux and provides a method to establish a qualitative interpretation. No abstract available
- |||||||||| argatroban / Generic mfg.
Trial completion date, Trial primary completion date: Monitoring Anticoagulation in Patients on ECMO for Severe Lung Failure (clinicaltrials.gov) - Mar 2, 2024 P=N/A, N=100, Completed, The results of this study suggest that further research into combination therapy with argatroban and antiplatelet agents may be warranted, however more rigorous RCTs are needed to definitively evaluate the effects of combination treatment. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Jul 2023
- |||||||||| heparin sodium injection / Generic mfg., cefuroxime / Generic mfg.
Journal: Case report of a rare fungal infection Kodamaea ohmeri in COVID-19 patient in North Malaysian hospital. (Pubmed Central) - Feb 23, 2024 The cause of death was multidrug-resistant sepsis with multiple organ failures due to COVID-19 infection, worsened by an embolism and trachea damage during a tracheostomy. To effectively manage K. ohmeri, clinicians and microbiologists must identify and be aware of this emerging human opportunistic pathogen, which can co-infect debilitated patients such as COVID-19 patients, for effective management.
- |||||||||| argatroban / Generic mfg.
Journal: Thrombosis prophylaxis following trauma. (Pubmed Central) - Feb 23, 2024 The standard dosing of subcutaneous LMWH is often insufficient for effective thrombosis prophylaxis in trauma patients. A more personalised approach, adjusting doses based on specific effect levels like anti-Xa or choosing an alternative mode of anticoagulation, could reduce the risk of insufficient prophylaxis and subsequent VTE.
- |||||||||| bivalirudin / Generic mfg.
Journal: Unresponsiveness of Activated Partial Thromboplastin Time to Bivalirudin in Adults Receiving Extracorporeal Membrane Oxygenation. (Pubmed Central) - Feb 22, 2024 In multivariable logistic regression, venovenous configuration (odds ratio [OR] = 2.83, 95% CI = 1.38-5.77) and higher fibrinogen concentration (OR = 1.22, 95% CI = 1.05-1.42) were associated with greater odds of unresponsiveness, whereas older age (OR = 0.79, 95% CI = 0.63-0.98), kidney dysfunction (OR = 0.48, 95% CI = 0.25-0.92), and a higher baseline aPTT (OR = 0.89, 95% CI = 0.82-0.97) were associated with lower odds. Alternative methods are necessary to ascertain bivalirudin's hemostatic impact when doses exceed 0.21?mg/kg/hr during ECMO.
- |||||||||| dabigatran etexilate / Generic mfg.
Journal: Dabigatran for Treatment and Secondary Prevention of Venous Thromboembolism in Pediatric Congenital Heart Disease. (Pubmed Central) - Feb 21, 2024 P3 In DOAC users, the risk of GIB was lower in edoxaban or apixaban subgroups than rivaroxaban or dabigatran subgroups. Data on favorable anticoagulant alternatives for the unmet needs of children with CHD are emerging, and our exploratory results suggest that dabigatran could be an appropriate treatment choice, although challenging sample size limitations in pediatric studies require cautious interpretation of findings.
- |||||||||| rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Journal, Surgery: Effect of direct oral anticoagulants on bleeding during and after cataract surgery. (Pubmed Central) - Feb 20, 2024 Data on favorable anticoagulant alternatives for the unmet needs of children with CHD are emerging, and our exploratory results suggest that dabigatran could be an appropriate treatment choice, although challenging sample size limitations in pediatric studies require cautious interpretation of findings. Cataract surgery was safely performed while continuing direct oral anticoagulation.
|